VIVA-INVESTMENT-PARTNERS
VIVA Investment Partners (VIP), the Swiss private equity firm which hosts the Follow the Entrepreneur (FTE) Investment Campaign and Summit , today announced a new round of speakers at the upcoming 10th Annual FTE Investor Summit taking place in Athens, Greece on October 10 – 14, 2020. The firm also revealed its top sponsors, which include Ernst & Young Greece and Piraeus Bank, the largest financial institution in Greece.
“We’re incredibly thankful to our sponsors and renowned speakers who are making this year’s FTE Investor Summit a massive success as it continues to be a must-attend event for the global financial community,” said Julie Meyer, Founder & CEO, VIP. “The world is being redesigned, and the entrepreneur will be at the heart of society and the economy as never before.”
Adding to the already impressive lineup of leading entrepreneurs, technologists and change-makers across all verticals, including, Tal Elyashiv of SPiCE VC, Eric Sarasin of Singularity Group and Harvey Griffiths of Horizon, the following individuals will be speaking at the FTE Summit next month:
- Christos Dimas, the Deputy Minister of Development and Investment, Hellenic Republic (Greece)
- Antigoni Lymperopoulou, seasoned Alternative Investments professional and CEO of Hellenic Development Bank of Investments (HDBI)
- Xavier Sarras, entrepreneur, investor & business development executive and mind behind the “Experience Quotient” (XQ)
Held at the Four Seasons Astir Palace in Athens, Greece, the FTE Investor Summit Greece 2020 will welcome more than 200 multi-family offices (MFO’s), sovereign wealth funds (SWF’s), high net worth individuals (HNWI’s), venture capital firms (VC’s) and corporate investors to share insight, inspiration, intelligence, and networking. The Summit also offers leading global investors and entrepreneurs to learn about new ecosystems and to identify opportunities in which to invest and grow.
VIP has also announced the Pre-Summit Activities, which include museum tours, wine tasting, day cruises to the most treasured landmarks in Greece and much more. All of these activities are included as part of the overall FTE Investor Summit experience.
For an invitation, to purchase tickets or inquire about partnership opportunities, visit www.globalftenetwork.com/buy-tickets/ , or contact the VIP Relations Manager Elizabeth Zachopoulou at elizabeth@vivacapital.co .
About VIVA Investment Partners:
VIVA Investment Partners was founded by successful entrepreneurs and venture capital investors to acquire equity stakes in and provide financing to established alternative asset managers (fund investments) and emerging growth companies (direct investments). To learn more about VIP, visit www.vivapartners.net/ , or email Liz Whelan at liz@lwprconsulting.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005759/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom